sgrs
2021-12-20
Oh no
Intercept Pharma Shares Stumble After Delay in Trial Data
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":693603001,"tweetId":"693603001","gmtCreate":1640009853269,"gmtModify":1640009853629,"author":{"id":3582199304143416,"idStr":"3582199304143416","authorId":3582199304143416,"authorIdStr":"3582199304143416","name":"sgrs","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Oh no</p></body></html>","htmlText":"<html><head></head><body><p>Oh no</p></body></html>","text":"Oh no","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693603001","repostId":1134420562,"repostType":4,"repost":{"id":"1134420562","kind":"news","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1640009445,"share":"https://www.laohu8.com/m/news/1134420562?lang=&edition=full","pubTime":"2021-12-20 22:10","market":"us","language":"en","title":"Intercept Pharma Shares Stumble After Delay in Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1134420562","media":"Dow Jones","summary":"Intercept Pharmaceuticals Inc.'s shares look set for a weak open Monday after the biopharmaceutical ","content":"<p>Intercept Pharmaceuticals Inc.'s shares look set for a weak open Monday after the biopharmaceutical company said top-line data from its late-stage trial of patients with compensated cirrhosis will be delayed.</p>\n<p>Intercept said the data is now expected in the first quarter of next year, rather than near the end of this year as previously anticipated.</p>\n<p>In premarket trading, the shares were 4.3% lower after ending Friday at $17.14, down more than 30% since the end of last year.</p>\n<p>Michelle Berrey, the company's chief medical officer and president of research and development, said Intercept teams continue to receive data and are working toward locking the database for the study.</p>\n<p>\"As a result of the magnitude and complexity of these analyses and recognizing that we are relying on external parties for information and services, we expect these analyses, including the completion of biopsy readings and safety adjudications, to continue into the first quarter of 2022,\" she said.</p>\n<p>The company said Reverse is the only active late-stage Phase 3 study in patients with compensated cirrhosis due to NASH, a serious disease for which there are no approved pharmacologic therapies. The liver biopsy samples from Reverse are being evaluated utilizing a new consensus methodology, it said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intercept Pharma Shares Stumble After Delay in Trial Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntercept Pharma Shares Stumble After Delay in Trial Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-20 22:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Intercept Pharmaceuticals Inc.'s shares look set for a weak open Monday after the biopharmaceutical company said top-line data from its late-stage trial of patients with compensated cirrhosis will be delayed.</p>\n<p>Intercept said the data is now expected in the first quarter of next year, rather than near the end of this year as previously anticipated.</p>\n<p>In premarket trading, the shares were 4.3% lower after ending Friday at $17.14, down more than 30% since the end of last year.</p>\n<p>Michelle Berrey, the company's chief medical officer and president of research and development, said Intercept teams continue to receive data and are working toward locking the database for the study.</p>\n<p>\"As a result of the magnitude and complexity of these analyses and recognizing that we are relying on external parties for information and services, we expect these analyses, including the completion of biopsy readings and safety adjudications, to continue into the first quarter of 2022,\" she said.</p>\n<p>The company said Reverse is the only active late-stage Phase 3 study in patients with compensated cirrhosis due to NASH, a serious disease for which there are no approved pharmacologic therapies. The liver biopsy samples from Reverse are being evaluated utilizing a new consensus methodology, it said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ICPT":"Intercept Pharmaceuticals"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134420562","content_text":"Intercept Pharmaceuticals Inc.'s shares look set for a weak open Monday after the biopharmaceutical company said top-line data from its late-stage trial of patients with compensated cirrhosis will be delayed.\nIntercept said the data is now expected in the first quarter of next year, rather than near the end of this year as previously anticipated.\nIn premarket trading, the shares were 4.3% lower after ending Friday at $17.14, down more than 30% since the end of last year.\nMichelle Berrey, the company's chief medical officer and president of research and development, said Intercept teams continue to receive data and are working toward locking the database for the study.\n\"As a result of the magnitude and complexity of these analyses and recognizing that we are relying on external parties for information and services, we expect these analyses, including the completion of biopsy readings and safety adjudications, to continue into the first quarter of 2022,\" she said.\nThe company said Reverse is the only active late-stage Phase 3 study in patients with compensated cirrhosis due to NASH, a serious disease for which there are no approved pharmacologic therapies. The liver biopsy samples from Reverse are being evaluated utilizing a new consensus methodology, it said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":553,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/693603001"}
精彩评论